Avoro Capital Advisors LLC 13D and 13G filings for Arrowhead Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 09:31 am Purchase | 2024-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | Avoro Capital Advisors LLC | 12,028,552 9.600% | 3,139,664 (+35.32%) | Filing |
| 2024-11-14 09:38 am Purchase | 2024-09-30 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | Avoro Capital Advisors LLC | 8,888,888 7.200% | 8,888,888 (New Position) | Filing |